Your browser doesn't support javascript.
loading
STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Perera, Samanthi A; Kopinja, Johnny E; Ma, Yanhong; Muise, Eric S; Laskey, Jason; Chakravarthy, Kalyan; Chen, Yiping; Cui, Long; Presland, Jeremy; Sathe, Manjiri; Javaid, Sarah; Minnihan, Ellen C; Ferguson, Heidi M; Piesvaux, Jennifer; Pan, Bo-Sheng; Zhao, Shuxia; Sharma, Sharad K; Woo, Hyun Chong; Pucci, Vincenzo; Knemeyer, Ian; Cemerski, Saso; Cumming, Jared; Trotter, B Wesley; Tse, Archie; Khilnani, Anuradha; Ranganath, Sheila; Long, Brian J; Bennett, David Jonathan; Addona, George H.
Afiliación
  • Perera SA; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey. perera.samanthi@gmail.com.
  • Kopinja JE; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Ma Y; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Muise ES; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, New Jersey.
  • Laskey J; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Chakravarthy K; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Chen Y; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Cui L; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Presland J; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Sathe M; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, New Jersey.
  • Javaid S; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, New Jersey.
  • Minnihan EC; Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Ferguson HM; Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Piesvaux J; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Pan BS; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Zhao S; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey.
  • Sharma SK; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey.
  • Woo HC; Department of Pharmacokinetics, Merck & Co., Inc., Kenilworth, New Jersey.
  • Pucci V; Department of Pharmacokinetics, Merck & Co., Inc., Kenilworth, New Jersey.
  • Knemeyer I; Department of Pharmacokinetics, Merck & Co., Inc., Kenilworth, New Jersey.
  • Cemerski S; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey.
  • Cumming J; Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey.
  • Trotter BW; Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey.
  • Tse A; Department of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey.
  • Khilnani A; Department of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey.
  • Ranganath S; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, New Jersey.
  • Long BJ; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Bennett DJ; Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey.
  • Addona GH; Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey.
Mol Cancer Ther ; 21(2): 282-293, 2022 02.
Article en En | MEDLINE | ID: mdl-34815361
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interferones / Inmunidad Innata / Inmunoterapia / Neoplasias Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interferones / Inmunidad Innata / Inmunoterapia / Neoplasias Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article